M. Camara
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Cancer, Hypoxia, and Metabolism, HER2/EGFR in Cancer Research, Metabolism, Diabetes, and Cancer, Cancer Treatment and Pharmacology
Most-Cited Works
- → Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial(2014)83 cited
- → Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study(2010)37 cited
- → Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study(2016)9 cited
- → Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): Efficacy analysis of the GEICAM/2003-10 trial.(2013)2 cited
- → 100 Inhibition of PDGFRalpha in tumor stroma with MEDI-575 enhances activity of carboplatin/paclitaxel and delays tumor regrowth in a NSCLC xenograft model(2010)1 cited
- → Prognostic factors in renal carcinoma(1997)1 cited
- → Extranodal Non-Hodgkin's lymphoma of the testis(1999)1 cited
- → The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathologic subtypes.(2013)
- → Abstract PS7-25: Geicam/2014-03 (RegisTEM): A prospective registry of unresectable locally advanced or metastatic breast cancer: Characteristics of a subset of patients with triple negative subtype(2021)
- → 57 Glioblastoma multiforme is characterized by high incidence of PDGFRalpha expression and susceptibility to the PDGFRalphaspecific antibody MEDI-575 in mouse tumor models(2010)